Navigation Links
Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
Date:4/21/2009

- Data Presented at the American Association for Cancer Research -

PRINCETON, N.J., April 21 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced preclinical efficacy and safety data from multiple programs, including antibodies to novel and potentially important cancer targets (CXCR4, fucosyl-GM1, glypican-3, mesothelin, CD70) and additional research in the area of antibody-drug conjugates. Data from the studies were presented at the Annual Meeting of the American Association for Cancer Research (AACR), April 18-22, 2009, in Colorado.

Characterization of MDX-1338, a human anti-CXCR4 antibody proposed for therapeutic application in AML and ALL (Abstract #LB-150)

CXCR4 is a seven-transmembrane, G-protein-coupled receptor in the CXC chemokine receptor family that is expressed on a variety of cancers including leukemias, lymphomas, breast, lung, colon, pancreatic, and ovarian cancer. In preclinical studies, MDX-1338, a fully human anti-CXCR4 antibody, effectively blocked the binding of CXCR4 to its ligand, CXCL12, thereby inhibiting chemotaxis and migration responses. In addition, MDX-1338 also reduced tumor growth in acute myelogenous leukemia and lymphoma xenograft models.

Efficacy of MDX-1110, an anti-Fucosyl-GM1 antibody in a SCLC tumor model (Abstract #838)

Fucosyl-GM1 is a ganglioside, a component of the cell plasma membrane, that is expressed on most small cell lung cancers (SCLC). In in vitro preclinical studies, a fully human, non-fucosylated anti-fucosyl-GM1 antibody, MDX-1110, demonstrated robust cytotoxic effector function (both antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity) for killing tumor cells. Additionally, MDX-1110 showed a favorable safety and toxicity profile. MDX-1110 also demonstrated potent anti-tumor a
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
2. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
3. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
4. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
5. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
7. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
8. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
9. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
10. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
11. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  Echo Therapeutics, Inc. ... company, today announced that, as it believes that ... needs beyond September 30, 2014, it has suspended ... and operations to conserve its liquidity and capital ... strategic review of Echo,s current financial position, funding ...
(Date:9/23/2014)... Transcatheter Heart Valve 2007 to 2020 - Europe ( ... , UK, Spain ) Summary GBI Research,s report, ... ( Germany , France , ... the transcatheter heart valves market in Europe . The analysis ... key company share data by revenue in 2013 for the following countries: ...
(Date:9/23/2014)... , Sept. 23, 2014 Ultrasound devices ... body in order to diagnose diseases and also ... surgical instruments while performing surgeries. This report studies ... parameters such as product type, technologies, applications and ... market, based on the product type has been ...
Breaking Medicine Technology:Echo Therapeutics Suspends Operations To Conserve Liquidity 2Echo Therapeutics Suspends Operations To Conserve Liquidity 3Echo Therapeutics Suspends Operations To Conserve Liquidity 4Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe (Germany, France, Italy, UK, Spain) 2Ultrasound Devices Market (By Product Type, By Technology and By Application - Obstetrics and Gynecology, Cardiovascular, Abdominal and Others) - Global Industry Analysis, Size, Share, Growth, Trends & Forecast, 2013 - 2019 2Ultrasound Devices Market (By Product Type, By Technology and By Application - Obstetrics and Gynecology, Cardiovascular, Abdominal and Others) - Global Industry Analysis, Size, Share, Growth, Trends & Forecast, 2013 - 2019 3
... OctreoPharm Sciences GmbH, a Berlin-based specialist in nuclear ... received the worldwide exclusive license for the development ... The new Gallium-68-labeled radioactive contrast agent ... has the potential to selectively detect and monitor ...
... 2011 Avista Capital Partners, a leading private equity ... the departing Chief Executive Officer of Nycomed, as Healthcare ... the development of Nycomed during Avista,s ownership of the ... Limited for Euro 9.6 billion. Under Mr. ...
Cached Medicine Technology:OctreoPharm Sciences GmbH Granted Global and Exclusive License for Oncology Diagnostic Product 2Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive 2Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive 3
(Date:9/23/2014)... 2014 Mel Frank, also known as ... and harvesting marijuana. He is perhaps one of the ... he’ll be leading a special elective course on growing ... pm at Oaksterdam University in Oakland, California. ... nomenclature, harvesting and manicuring, and identifying preflowers and outdoor ...
(Date:9/23/2014)... September 23, 2014 Oaksterdam University has ... . In its first post, the University addresses the ... changing cannabis industry. , The cannabis industry is becoming ... is expecting an 18-month boost of more than $600 ... use pot sales. And, the new legal recreational marijuana ...
(Date:9/23/2014)... Mo. Infants, vocalizations throughout the first year ... and cooing to forming syllables and first words. ... amount of vocalizations may differ between hearing and ... that infant vocalizations are primarily motivated by infants, ... with profound hearing loss who received cochlear implants ...
(Date:9/23/2014)... 23, 2014 Florida Hospital Zephyrhills ... renovated Women’s Health Center on Wednesday, September 24. ... the specially designed center offers a new level ... County. The Women’s Health Center offers comprehensive women’s ... labor and delivery through The Baby Place®, and ...
(Date:9/23/2014)... 23, 2014 "The primary purpose of the ... an inventor from Sacramento, Ca.. "Call lights are often found ... hanging on the IV pole out of the patient's reach. ... call device whenever they need it, I created this caddy." ... the nurse call device within easy reach. The accessory ensures ...
Breaking Medicine News(10 mins):Health News:Special Elective Course Added to Oaksterdam University Schedule; Unique Opportunity to Learn From the “Godfather of Cannabis” Mel Frank on September 27, 2014 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 3Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 3
... cancer when it works with,the growth-promoting protein IL-3 and ... Tenn., Nov. 27 A gene called N-Myc,leads a ... is overexpressed,helping to trigger acute myeloid leukemia (AML) under ... conditions, according to,results of a mouse study done by ...
... CHAPEL HILL, N.C., Nov. 27 A story ... "colleague spam" -- the habit of,co-workers indiscriminately hitting ... New research by benchmarking leader Best Practices, LLC,uncovered ... spam" -- the,tendency of organizations to send redundant ...
... Failing Marks for Second Straight Year, WASHINGTON, Nov. ... Report Card on Lung Cancer. This,Report is an assessment ... state of Georgia. LCA-GA is a chapter of Lung ... patient support and,advocacy for people living with or at ...
... Nov. 27 The Aesthetic Extender,Symposium announced its inaugural ... which will be held in Miami Beach,Florida on October ... the first,and only event of its kind. Unlike other ... its mission statement a goal of adhering to,the policies ...
... Nov. 27 A new, free white ... on choosing the,right electronics manufacturing services (EMS) ... to download at, http://www.federalelec.com/medicalpaper ., Medical ... consistent quality and,conformance to product and regulatory ...
... E.S.T. - Positron emission tomography (PET) is a useful ... staging of lung cancer and improved treatment for patients, ... Journal of National Cancer Institute. , The ... of Cancer Care Ontarios Program in Evidence-Based Care led ...
Cached Medicine News:Health News:St. Jude Researchers Identify Key Genetic Trigger of Acute Myeloid Leukemia 2Health News:Using Efficient Communication to Boost Pharma Sales Force Productivity 2Health News:Lung Cancer Alliance-Georgia Issues Second Annual State-Specific Report Card on Lung Cancer 2Health News:Lung Cancer Alliance-Georgia Issues Second Annual State-Specific Report Card on Lung Cancer 3Health News:White Paper Details How to Choose the Right EMS Provider for Medical Products Outsourcing 2Health News:PET imaging significantly enhances standard imaging in lung cancer staging 2
The Properdin ELISA Kit is approved for in-vitro diagnostic use and measurement of properdin serum levels, relevant in cases of recurrent meningococcal infection and recurrent bacterial meningitis....
Inquire...
... can be used for a variety of vacuum needs ... or volatile fumes., Quiet running operation ... changes forever , Chemically Resistant ... solvents such as acids and organics. ...
High-intensity 300-watt xenon lamp, with continuously adjustable output from 0 to 100% manually or automatically by camera video output signal....
Medicine Products: